SCHEMBL5895673

SCHEMBL5895673

O=C(O)/C(=C/c1ccc(Oc2cccc(Cl)c2)cc1)NC(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.57
ALDH1A1 P00352 5/20 0.52
MAPT P10636 2/20 0.47
ALOX12 P18054 2/20 0.46
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HDAC8 Q9BY41 1/20 0.45
SERPINE1 P05121 1/20 0.45
GLA P06280 1/20 0.44
PGR P06401 2/20 0.44
EPHX1 P07099 1/20 0.43
ITGB1 P05556 1/20 0.43
ITGA4 P13612 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
AKR1C3 P42330 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5895691 1.00 LMNA (0.57) LMNAALDH1A1MAPTALOX12HTT
SCHEMBL5895684 1.00 LMNA (0.57) LMNAALDH1A1MAPTALOX12HTT
SCHEMBL5896916 0.89 ALDH1A1 (0.61) LMNAALDH1A1MAPTALOX12HTT
SCHEMBL5896926 0.89 ALDH1A1 (0.61) LMNAALDH1A1MAPTALOX12HTT
SCHEMBL5896931 0.89 ALDH1A1 (0.61) LMNAALDH1A1MAPTALOX12HTT
SCHEMBL5896842 0.88 LMNA (0.67) LMNAALDH1A1MAPTALOX12HTT
SCHEMBL5896831 0.88 LMNA (0.67) LMNAALDH1A1MAPTALOX12HTT
SCHEMBL5896837 0.88 LMNA (0.67) LMNAALDH1A1MAPTALOX12HTT
SCHEMBL5899810 0.86 PGR (0.61) LMNAALDH1A1MAPTHTTCYP2C9
SCHEMBL5899811 0.86 PGR (0.61) LMNAALDH1A1MAPTHTTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 LMNA 4118/4885ALDH1A1 832/4885MAPT 3583/4885
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI LMNA 4047/4885ALDH1A1 1400/4885MAPT 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.